First Twenty-Five Percent of Subjects in Provectus’ Phase 2 Melanoma Clinical Trial Treated
News Jul 08, 2008
Provectus Pharmaceuticals, Inc. has announced that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in Provectus Pharmaceuticals’ Phase 2 clinical trial of PV-10.
Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia.
In addition, Provectus anticipates opening the first United States site for the trial in the very near future. Currently, Provectus is also sponsoring Phase 2 trials for psoriasis and atopic dermatitis in New York and Florida.
In Australia, the trials are currently being conducted at the Sydney Melanoma Unit under the supervision of John F Thompson, MD, and at the Princess Alexandra Hospital in Brisbane, Queensland, under Mark Smithers, MD.
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019